Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable ...
NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord ...
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life ...
Researchers at Children's Hospital of Philadelphia (CHOP) and Children's National Hospital in Washington D.C. are uncovering ...
Medical Device Network on MSN
FDA clears Onward’s ARC-EX System for home use in spinal cord injury care
The US Food and Drug Administration (FDA) has granted 510(k) clearance for the expanded use of Onward Medical’s ARC-EX System ...
ONWARD Medical N.V. (Euronext: ONWD - US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore ...
Ventoux Biosciences is a biotechnology company developing locally delivered therapies for immune-fibrotic diseases. Founded by a patient with Dupuytren's disease and led by seasoned biotech executives ...
Liverpool specialist nurse and Manchester Arena bombing survivor were on hand for advice as Tyrone undergoes physio after hit ...
The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular ...
Cerebrospinal fluid (CSF) is a clear and watery liquid that flows in and around the brain and spinal cord. Its functions ...
NervGen Pharma ( ($TSE:NGEN) ) has shared an announcement. NervGen Pharma has reported significant advancements in its CONNECT SCI Study, ...
Beneath the surface of your gut lies a vast network of neurons—as many as in your spinal cord. New research from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback